Most material SEC filings — October 19, 2026

On July 29, 2026, CBIZ entered a definitive merger agreement with Grant Thornton (backed by New Mountain Capital) to be acquired in an all-cash transaction valued at $5.0 billion, or $55.00 per share. The deal is expected to close in Q4 2026, subject to shareholder approval and regulatory clearance. Following completion, CBIZ will become a private company and delist from the NYSE. Q3 2026 results showed revenue of $702M (+1.2% YoY), net income of $47M (+56.7%), and adjusted EBITDA of $132M (+6.3%).

Metaplanet Holdings will invest 2,100 Bitcoin (valued at ~$132.1M on August 14, 2026 reference date; ~$170M as of October 16) plus $2.5M cash into Super League in exchange for 44.86M common shares at $3.00/share, 100 convertible preferred shares, and ten-year warrants for up to 381M shares. Super League will be renamed Superplanet, Inc., trade as SUPA on Nasdaq, and become Metaplanet's U.S. Bitcoin treasury platform; closing anticipated Q4 2026 subject to customary conditions. Matt Edelman continues as CEO; Metaplanet faces a five-year lock-up on received shares.

Open World, Inc. (NASDAQ: OPNW, ~$8.0M market cap) signed a definitive merger agreement dated October 16, 2026 to acquire Blocksight Holdings Co. from sellers Kim Associates Advisory Inc., Patrick Kim, Ryan Yue, and Sungmeen Hong. Purchase price: 641,924 shares of OpenWorld common stock (4.0% of fully diluted capitalization post-business combination), with 275,110 restricted shares vesting monthly over 22–36 months. Sellers receive signing bonuses ($357,350 for Kim, $142,650 for Hong), six-month and twelve-month milestone bonuses (identical amounts), and retention bonuses payable at 24 and 36 months (each $536,025 and $213,975 respectively). Blocksight's AI agents automate RWA tokenization workflows; OpenWorld announced concurrent non-binding term sheets with BeyondAI (~$130M IP-backed deal, Oct 7) and Meridian (~$1B distributed solar/AI computing program, Oct 15).

Barnwell Industries agreed to sell its Canadian oil and gas business to an unnamed local Canadian corporation for a base price of C$9 million (C$4 million cash + C$5 million 5% gross overriding royalty), signed October 5, 2026. Barnwell retains a 5% royalty on future wells and an option for the buyer to purchase that royalty for C$5 million post-closing. The transaction is subject to closing conditions and shareholder approval; a C$1 million deposit is held in escrow.

Rekor Systems filed a Delaware Court of Chancery complaint on October 16, 2026 against former director Viraj Mehta, alleging he breached fiduciary duties by: (1) falsely claiming familiarity with Anson Fund (the financing buyer) when he had learned of it only the evening before the vote; (2) concealing that his fund Arctis planned to distribute its entire ~12.3 million Rekor shares (9% of company) post-lockup while keeping $5 million in secured revenue notes; (3) failing to disclose these conflicts while steering the Board toward the Anson deal. The financing closed December 16, 2025 with Anson purchasing 8,571,428 units at $1.75 for $15M, issuing seven-year warrants and imposing restrictions including a variable-rate ban and 30% participation right through December 2027. Rekor claims Anson sold all common stock within Q1 2026 and Arctis distributed shares on March 25, 2026 (the record date), both creating selling pressure and preventing quorum at annual meetings.

Disc Medicine announced that bitopertin successfully met both co-primary endpoints and all secondary endpoints in the APOLLO Phase 3 trial of 183 patients with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP). Key results: 41.4% reduction in protoporphyrin IX (PPIX) versus placebo (p<0.0001), 12.2-hour increase in average monthly time in light without pain during month 6 versus placebo (p=0.0010), 71% reduction in phototoxic reaction incidence rate versus placebo (p<0.0001), and statistically significant improvements in quality-of-life measures (PGIC and PGIS, p<0.0001). Bitopertin was well-tolerated with dizziness (50% of treated patients, mild-to-moderate and transient) as the most common adverse event; no new safety signals observed. Disc plans to resubmit an NDA to the FDA by end of 2026, with an FDA decision anticipated by mid-2027.

On December 19, 2025, reAlpha Tech Corp. agreed to acquire InstaMortgage Inc. for approximately $8.5 million in total consideration: $500,000 cash, $1.5 million reAlpha stock, and $6.5 million in six semiannual installments over three years (minimum $1.5 million in cash). InstaMortgage generated $7.3–9.7 million in loan origination revenue for FY2025 with net income of $91–95k; the company holds $9.9 million loans held for sale, $9.8 million warehouse debt, and $1.27 million stockholder equity. The merger was unsigned as of December 31, 2025, pending regulatory approvals.

EyePoint's LUCIA Phase 3 trial (475 patients) missed its primary non-inferiority endpoint for DURAVYU 2.7mg versus aflibercept in wet AMD: DURAVYU achieved +2.5 letter BCVA gain versus aflibercept's +6.1 letters (−3.7 letter difference, CI outside −4.5 letter non-inferiority margin). However, LUCIA met key secondary endpoints including 38% reduction in treatment burden (p=0.0001 nominal), 52% supplement-free rate through Week 56, and strong anatomic control (−66 μm CST reduction). Both Phase 3 wet AMD trials (LUGANO and LUCIA, ~907 patients total) failed primary endpoints despite secondary successes. Safety profile remained favorable. Company redirects focus to DME program; Phase 3 COMO and CAPRI trials expected to report topline in Q4 2027.

EquipmentShare increased full-year 2026 Rental Segment revenue growth guidance from 33% to 43% (midpoint), raising total revenue guidance to $5.8B–$6.0B (prior: $5.3B–$5.7B) and Adjusted Core EBITDA to $2.1B–$2.2B (prior: $1.9B–$2.1B). The company also projects 427–435 full-service rental locations and maintains long-term Core EBITDA run-rate target of ~$4B, citing strong customer demand and high fleet utilization across its expanding network.

Silgan Holdings is combining its Metal Containers segment and Food & Beverage Flat Cap Closures business with Trivium Packaging in an all-cash acquisition valued at $3.4B enterprise value (7.1x LTM EBITDA, or 4.8x post-synergies). Silgan will contribute businesses valued at $3.8B (8.1x LTM EBITDA), receive ~$2.3B cash proceeds, retain 60% ownership of the new Silgan Metal Containers & Closures (MCC) entity, while American Industrial Partners contributes ~$1.0B equity for 40% ownership. Expected $225M synergies by year 3; transaction expected to close mid-2027 and deliver ≥15% EPS and FCF accretion. Silgan's Dispensing Solutions remains wholly owned.

CorMedix announced FDA acceptance for Priority Review of a supplemental NDA for REZZAYO (rezafungin) for prophylaxis of invasive fungal disease in adults undergoing allogeneic HSCT, with PDUFA target action date in Q1 2027. The sNDA is supported by positive Phase III ReSPECT topline results announced in April. If approved, the company targets promotional launch in H2 2027. Mundipharma is the global development partner and submitter of the application.

Clene Inc. announced submission of a New Drug Application (NDA) to the FDA in October 2026 seeking accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis (ALS) treatment, based on neurofilament light chain biomarker data and clinical outcomes. The company is simultaneously preparing a confirmatory Phase 3 RESTORE-ALS study. No financial figures, partnership details, or specific efficacy data are disclosed in this announcement.

President Zhang Jason Gechen (APLD) bought 300K shares (~$5.7M) on the open market (9.6% of holdings). Open-market insider purchase — historically a bullish signal.

CEO; Chairman Cummins Wes (APLD) bought 56K shares (~$1.0M) on the open market (0.9% of holdings). Open-market insider purchase — historically a bullish signal.

As of LTM Q3'26, Jefferies Financial Group achieved $8.5B in net revenues (+119% since 2019) and $937M net earnings (+123% since 2019), with 13.1% adjusted ROTE (+726 bps since 2019). The firm announced its pending acquisition of a 50% interest in Hildene Holding Company (which is acquiring SILAC, a life/annuity insurance company), integrating structured credit and insurance solutions into its asset management platform. Jefferies also announced a Japan equities joint venture with SMBC launching January 1, 2027, combining both firms' Japan businesses to create a #1 franchise.

Cleveland-Cliffs reported Q3 2026 revenues of $5.6 billion (+7.7% Q-o-Q) and adjusted EBITDA of $612 million (up $326 million vs. Q2's $286 million), representing the strongest quarter in three years. GAAP net income was $165 million ($0.26/share) vs. Q2's loss of $134 million. Management raised 2027 outlook to adjusted EBITDA exceeding $4 billion based on new customer contracts and pricing; however, idled Stelco's galvanizing lines (~2,000 Canadian jobs indefinitely idle) due to oversupply in Canadian galvanized steel market. Liquidity stands at $3.2 billion; management targeting <2.5x net debt/EBITDA by mid-2027.

Marker Therapeutics received a $2.6 million non-dilutive FDA Orphan Products Clinical Trials grant (one of six selected from 66 applications in FY2026) to fund a Phase 1 study of MT-601 in locally advanced unresectable pancreatic cancer, with clinical initiation anticipated in Q1 2027. The grant supports a program building on prior Baylor College of Medicine data showing 84.6% disease control rate and 14.1-month median overall survival, compared to 9.2–11.1 months for standard chemotherapy. Marker has also secured complementary non-dilutive funding from NIH SBIR and CPRIT for this program.